In silico and pharmacokinetic studies of glucomoringin from Moringa oleifera root for Alzheimer’s disease like pathology

Future Sci OA. 2024 May 15;10(1):2340280. doi: 10.2144/fsoa-2023-0255. eCollection 2024.

ABSTRACT

Aim: The aim of this research is to investigate the potential of glucomoringin, derived from Moringa oleifera, as a therapeutic agent for Alzheimer’s disease through in silico analysis. Materials & methods: This study employs in silico or computational methodologies, including pkCSM, Swiss ADME, OSIRIS® property explorer, PASS online web resource and MOLINSPIRATION® software, to predict the pharmacokinetic characteristics and biological activity of glucomoringin. Results & conclusion: Molecular docking indicates strong binding to I-1β and the pharmacokinetic profile shows cytochrome P450 enzyme inhibition, prompting further research for dosing strategies. Toxicological predictions affirm safety, while bioactivity assessments demonstrate versatility in modulating essential pathways. glucomoringin’s potential for Alzheimer’s treatment, emphasizing the need for additional empirical research.

PMID:38817392 | PMC:PMC11137837 | DOI:10.2144/fsoa-2023-0255